Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study
Among hemodialysis patients with high risk of bleeding, anticoagulation with NM, compared with citrate anticoagulation, provided relatively better efficacy, with no bleeding increment. NM is a valid alternative to citrate for hemodialysis patients at high risk of bleeding.
Authors
- Lirui Wang (ORCID: https://orcid.org/0000-0001-9285-7084)
- Ying Zhou (ORCID: https://orcid.org/0000-0001-8992-7897)
- Jiangtao Li (ORCID: https://orcid.org/0000-0001-9225-6748)
- Yue Chen (ORCID: https://orcid.org/0000-0003-4863-0864)
- Yuqiu Lu
Institutions
- Tongji University (CN)
- Tongji Hospital (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1080/0886022x.2025.2464830
- Citations
- 5
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 6.94